John Libbey Eurotext

European Journal of Dermatology


Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia Article à paraître


Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

Recently, the anti-programmed cell death protein 1 (PD-1) inhibitor, nivolumab, and the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, ipilimumab, have been proven effective in treating Asian melanoma patients [1, 2]. However, group comparisons in clinical trials are lacking, and the superior efficacy of combined anti-PD-1 and anti-CTLA-4 therapy relative to anti-PD-1 monotherapy has not been demonstrated in Asian melanoma studies. We retrospectively analysed the efficacy of [...]